9 Results for "

CCDC6-RET

" in MedChemExpress (MCE) Product Catalog:
Products (9)

9 Results for "CCDC6-RET" in MCE Product Catalog:

17
17 Cited Publications
Cat. No.: HY-112301
CAS No.: 2097132-94-8
Purity:  99.98%
Synonyms: BLU-667
Target:  

RET

Research Areas:  

Cancer

Pralsetinib (BLU-667) is a highly potent, selective RET inhibitor. Pralsetinib (BLU-667) inhibits WT RET, RET mutants V804L, V804M, M918T and CCDC6-RET fusion with IC50s of 0.4, 0.3, 0.4, 0.4, and 0.4 nM, respectively .
loading...
    loading...
Cat. No.: HY-178061
CAS No.: 2598870-24-5
Target:  

ERK RET

Research Areas:  

Cancer

APS03118 is an orally active, potent and selective rearranged during transfection (RET) inhibitor. APS03118 broadly inhibits RET fusions and mutations (including G810, V804, L730, and Y806 variants), with IC50 values predominantly below 1 nM (0.095 nM for WT; ranging from 0.00438 to 5.72 nM for mutants), and demonstrates marked superiority against RET G810 mutations. APS03118 inhibits the entire RET signaling pathway (including RET, Shc, and ERK1/2), with >20-fold selectivity over most off-target kinases (except FLT3 and YES). APS03118 induces complete tumor regression in KIF5B-RET and CCDC6-RET V804 M patient derived xenografts (PDXs) and significantly prolongs survival in an intracranial CCDC6-RET metastasis mice model. APS03118 can be used for selective RET inhibitor (SRI)-resistant, RET-driven cancer research .
loading...
    loading...
Cat. No.: HY-133551
CAS No.: 2561413-77-0
Purity:  99.63%
Target:  

RET

Research Areas:  

Neurological Disease Cancer

WF-47-JS03 is a potent, selective and brain-penetrantRET kinase inhibitor with IC50s of 1.7 nM and 5.3 nM for KIF5B-RET transfected Ba/F3 cells and CCDC6-RET transfected LC-2/ad lung cancer cells, respectively. WF-47-JS03 demonstrates >500-fold selectivity against kinase insert domain receptor (KDR) .
loading...
    loading...
Cat. No.: HY-112301R
CAS No.: 2097132-94-8
Synonyms: BLU-667 (Standard)
Target:  

Reference Standards RET

Research Areas:  

Cancer

Pralsetinib (Standard) is the analytical standard of Pralsetinib. This product is intended for research and analytical applications. Pralsetinib (BLU-667) is a highly potent, selective RET inhibitor. Pralsetinib (BLU-667) inhibits WT RET, RET mutants V804L, V804M, M918T and CCDC6-RET fusion with IC50s of 0.4, 0.3, 0.4, 0.4, and 0.4 nM, respectively .
loading...
    loading...
Cat. No.: HY-170809
Target:  

RET

Research Areas:  

Cancer

RET-IN-29 (Compound 8W) is a selective RET kinase inhibitor. RET-IN-29 exhibits inhibitory potency against the BaF3 cells harboring CCDC6-RET V804M mutation with an IC50 value of 0.715 μM. RET-IN-29 is promising for research of non-small cell lung cancer (NSCLC) .
loading...
    loading...
Cat. No.: HY-170926
Target:  

RET Apoptosis

Research Areas:  

Cancer

CQ1373 is a potent RET inhibitor, demonstrating cellular potency with IC50 values of 13.0, 25.7 and 28.4 nM against BaF3 cells expressing CCDC6-RET, CCDC6-RET-G810C and CCDC6-RET-G810R, respectively. CQ1373 exhibits good selectivity toward wild-type RET and solvent front mutants G810C/R with IC50 values of 4.2, 7.1 and 32.4 nM, respectively. CQ1373 inhibits RET phosphorylation and downstream signaling through SHC. CQ1373 induces Apoptosis and cell cycle arrest in BaF3 cells. CQ1373 exhibits anti-tumor efficacy and can be used for cancer research .
loading...
    loading...
Cat. No.: HY-181895
Target:  

HyT RET

Research Areas:  

Cancer

RET degrader-1 is a HyT degrader targeting RET. RET degrader-1 induces the degradation of CCDC6-RET via the ubiquitin-proteasome pathway. RET degrader-1 can be used in the research of RET-driven cancers .
loading...
    loading...
Cat. No.: HY-144131
CAS No.: 2764891-88-3
Target:  

Apoptosis RET

Research Areas:  

Cancer

RET-IN-11 is a potent and selective RET inhibitor with IC50s of 6.20 nM, 18.68 nM for RET and RET V804M, respectively. RET-IN-11 shows anti-proliferation and migration activity in CCDC6-RET-driven LC-2/ad cells. RET-IN-11 induces cell apoptosis .
loading...
    loading...
Cat. No.: HY-125014
CAS No.: 2095172-11-3
Target:  

RET STAT Akt

Research Areas:  

Cancer

RET-IN-2 is a selective RET inhibitor with an IC50 of 61.2 nM. RET-IN-2 inhibits the phosphorylation of RET and its downstream STAT3 and AKT proteins in BaF3/CCDC6-RET cells. RET-IN-2 inhibits the proliferation of RET fusion-positive cells. RET-IN-2 can be used for cancer-related research .
loading...
    loading...